Skip to main content
. 2021 Mar 5;10(5):1085. doi: 10.3390/jcm10051085

Figure 4.

Figure 4

Mean percentage of BMD loss at week 52 (lumbar spine) in the different group of women treated by different doses of GnRH antagonist (elagolix and linzagolix). Patients randomized to linzagolix 200 mg were switched to linzagolix 100 mg at week 24.